Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Howard Capital Management Inc.

Howard Capital Management Inc. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,380 shares of the life sciences company’s stock after purchasing an additional 155 shares during the quarter. Howard Capital Management Inc.’s holdings in Illumina were worth $719,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc grew its position in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the 4th quarter worth about $32,000. TD Private Client Wealth LLC boosted its stake in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. V Square Quantitative Management LLC grew its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 132 shares during the period. Finally, First Horizon Advisors Inc. increased its stake in shares of Illumina by 73.5% in the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock valued at $59,000 after purchasing an additional 186 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Down 0.3 %

ILMN stock opened at $93.96 on Tuesday. The company’s 50 day moving average price is $126.97 and its 200 day moving average price is $133.99. The firm has a market capitalization of $14.88 billion, a price-to-earnings ratio of -12.23, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a fifty-two week low of $92.20 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Robert W. Baird increased their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.